The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Membranous nephropathy (MN) may also be secondary to many other diseases (e.g., infections, drugs, neoplasms and autoimmune diseases). In this study, the presence of Helicobacter Pylori (H. pylori) antigen was investigated in renal tissue from needle biopsy samples, and the prevalence of H. pylori infection and the effects of H. pylori eradication on proteinuria level in patients with MN will be investigated.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Istanbul University
• Treatments: Amoxicillin; Clarithromycin; Dexlansoprazole; Lansoprazole

Criteria

Inclusion Criteria:

• Age between 18-70 years

• Nondiabetic patients

• Patients with primary glomerulonephritis

• Clinical diagnosis of membranous nephropathy, IgA nephropathy or focal segmental glomerulosclerosis confirmed by biopsy

• Glomerular filtration rate > 30 mL/min

• Patients who did not receive Helicobacter pylori eradication therapy within the last three months before enrollment in study

Exclusion Criteria:

• Patients with secondary glomerulonephritis

• Glomerular filtration rate < 30 mL/min

• Patients who received Helicobacter pylori eradication therapy within the last three months before enrollment in study

• Patients with a history of gastric surgery

• Patients without an informed consent